Core Insights - Pelthos Therapeutics Inc. has launched the "Moms Against Molluscum" movement to support families dealing with molluscum contagiosum, a highly contagious skin infection affecting millions, particularly children [1][8]. Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on developing innovative therapeutic products for unmet patient needs, with its lead product being ZELSUVMI™ (berdazimer) topical gel, approved for treating molluscum contagiosum [13]. Product Information - ZELSUVMI is a topical nitric oxide-releasing gel, effective for treating molluscum in patients aged one year and older, and is the first FDA-approved at-home treatment for this condition [4][10]. - The product was launched in July 2025 and is designed for convenient application, allowing treatment at home or on-the-go [4][10]. Market Context - Molluscum contagiosum affects an estimated 16.7 million people in the U.S., with around 6 million new cases annually, primarily among children [2][7]. - Approximately 41% of children with molluscum will transmit the infection to others in their household, highlighting the need for effective treatment options [2]. Community Engagement - The "Moms Against Molluscum" movement aims to empower families to share their experiences and educate them about new treatment options, fostering a supportive community [5][6]. - Pelthos is actively promoting this initiative through social media to raise awareness and encourage discussions about molluscum contagiosum [6].

Recent Company Highlights DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy operations for the three and six months ended June 30, 2025. This will be the last set of financial results that the Company will issue solely related to the business operations of Channel Therapeu ...